1/2 Doxycycline for Emphysema in People Living With HIV (The DEPTH Trial) (DEPTH)
Overview
Organization: National Heart, Lung, and Blood Institute
Start Date: 08/2022
End Date: 02/2027
Primary Goal: Goal 4: Increase and sustain research to better understand the prevention, pathogenesis, diagnosis, treatment, and management of COPD.
Secondary Goal(s):
Objective(s):
- Help expand, coordinate, and optimize COPD research efforts
- Improve methods for earliest detection and diagnosis and develop effective strategies for preventing the onset and progression of COPD
- Develop personalized medicine for COPD based on the pathogenesis and clinical heterogeneity
- Promote research that can lead to strategies that help prevent the onset and progression of COPD and improve the quality of COPD care and management
Collaboration: Weill Medical College of Cornell University
Activity Type: Research
Activity Description
This NHLBI-funded research activity is being carried out by Weill Medical College of Cornell University.The purpose of this study is to determine if doxycycline will reduce progression of emphysema in people living with HIV. The secondary objectives are to examine the effects of doxycycline on change in quantity of emphysema, six minute walk distance, patient reported outcomes, ratio of forced expiratory volume in 1 second and forced vital capacity. Secondary objectives will also describe the safety and tolerability of doxycycline and determine if doxycycline is associated with development of antibiotic-resistant bacterial infections.
Audience
General Audience: Health professionals, Researchers
Focused Audience: n/a
Program Reach: National
Type of Area: N/A
Setting: Workplace
Cost and Funding Sources
This activity was funded through the National Heart, Lung, and Blood Institute.Impact Analysis
Results of program are in progressAdvice or Lessons Learned
In processContact Information
National Heart, Lung, and Blood Institute
Program Analyst
Bethesda
Maryland